Treatment of anaemia in inflammatory bowel disease with iron sucrose

Scandinavian Journal of Gastroenterology

Volumn 39, Issue 5, 2004, Pages 454-458

  Bodemar, G ^b   Kechagias, S ^a   Almer, S ^b   Danielson, B G ^b  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

Anaemia; Inflammatory bowel diseases; Infusions; Intravenous; Iron deficiency; Therapeutics

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; FERRIC HYDROXIDE SUCROSE; FERRITIN; HEMOGLOBIN; MERCAPTOPURINE; MESALAZINE; SALICYLIC ACID;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; CONTROLLED STUDY; DISEASE ASSOCIATION; ENTERITIS; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HOSPITAL; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 2442490748     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365520310008818-1     Document Type: Article

References (14)

1. Oldenburg B, van Berge Henegouwen GP, Rennick D, Van Asbeck BS, Koningsberger JC. Iron supplementation affects the production of pro-inflammatory cytokines in IL-10 deficient mice. Eur J Clin Invest 2000;30:505-10.
2. Oldenburg B, Koningsberger JC, van Berge Henegouwen GP, Van Asbeck BS, Marx JJ. Review article: iron and inflammatory bowel disease. Aliment Pharmacol Ther 2001;15:429-38.
3. Erichsen K, Hausken T, Ulvik RJ, Svardal A, Berstad A, Berge RK. Ferrous fumarate deteriorated plasma antioxidant status in patients with Crohn disease. Scand J Gastroenterol 2003;38:543-8.
4. Cronin CC, Shanahan F, editors. Anemia in patients with chronic inflammatory bowel disease. Am J Gastroenterol 2001;96:2296-8.
5. Schreiber S, Howaldt S, Schnoor M, Nikolaus S, Bauditz J, Gasché C, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med 1996;334:619-23.
6. Danielson BG, Salmonson T, Derendorf H, Geisser P. Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung 1996;46:615-21.
7. Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneim-Forsch/Drug Res 1992;42:1439-52.
8. Macdougall IC, Bailie G, Richardson D. Worldwide safety profile of iron sucrose injection (Venofer®): Analysis of 1,004,477 patients from 1992 to 2001. ASN 2001. p. A2036.
9. Venofer Product Monograph. April 2000Vifor (International) Inc., St Gallen, Switzerland.
10. Bothwell TM, Finch CA. Iron Metabolism. 1st ed. Boston: Little, Brown & Co.; 1962. p. 297.
11. Gasché C, Dejaco C, Waldhoer T, Tillinger W, Reinisch W, Feuger GF, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized controlled trial. Ann Intern Med 1997;126:782-7.
12. Gasché C, Waldhoer T, Feichtenschlager T, Male C, Mayer A, Mittermaier C, et al. Prediction of response to iron sucrose in inflammatory bowel disease associated anemia. Am J Gastroenterol 2001;96:2382-7.
13. Andersson P, Olaisson G, Bodemar G, Almer S, Arvidsson M, Dabrosin-Söderholm J, et al. Low symptomatic load in Crohn disease with surgery and medicine as complementary treatment. Scand J Gastroenterol 1998;33:423-9.
14. Andersson P, Olaisson G, Bodemar G, Nyström PO, Sjödahl R. Surgery for Crohn colitis over a twenty-year period: fewer stomas and the replacement of total colectomy by segmental resection. Scand J Gastroenterol 2002;37:68-73.